Recent Updates
Recently added Catalysts
RIGL Positive Sentiment Score: 70/100

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Friday, October 6, 2023 1 min read
Key Takeaway: Rigel Pharmaceuticals has announced the granting of 285,800 stock options to seven non-executive employees, which will vest over four years with a one-year cliff. This initiative is part of Rigel's Inducement Plan approved by its Board of Directors, following NASDAQ Listing Rule 5635(c)(4). The plan aims to enhance employee recruitment and retention by providing long-term incentives. Rigel continues its commitment to developing novel therapies for hematologic disorders and cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel has successfully granted 285,800 stock options, which can attract and retain talent.
  • The inducement grant aligns with Rigel's strategic goals under NASDAQ Listing Rule 5635(c)(4).

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 285,800 stock options to seven non-executive employees vesting over four years with a one-year cliff.
Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Investors & Media Contacts:
Rigel Pharmaceuticals, Inc.
Email: [email protected]
SOURCE Rigel Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What did Rigel Pharmaceuticals announce on October 6, 2023?

Rigel Pharmaceuticals announced awards granted under its Inducement Plan to new employees.

How many stock options did Rigel grant?

Rigel granted 285,800 stock options to seven non-executive employees.

What is the vesting period for the stock options?

The stock options vest over four years with a one-year cliff.

What is the focus of Rigel Pharmaceuticals?

Rigel focuses on developing novel therapies for hematologic disorders and cancer.

Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals NASDAG Rule 5635 stock options employee retention biotechnology
Last updated: Oct 6, 2023